185 related articles for article (PubMed ID: 24457057)
21. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694.
Tarhini AA; Stuckert J; Lee S; Sander C; Kirkwood JM
J Clin Oncol; 2009 Jan; 27(1):38-44. PubMed ID: 19047287
[TBL] [Abstract][Full Text] [Related]
22. Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I-IIA cutaneous melanoma.
Meyer S; Buser L; Haferkamp S; Berneburg M; Maisch T; Klinkhammer-Schalke M; Pauer A; Vogt T; Garbe C
Eur J Cancer; 2023 Mar; 182():77-86. PubMed ID: 36753835
[TBL] [Abstract][Full Text] [Related]
23. D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress.
Desch A; Gebhardt C; Utikal J; Schneider SW
Int J Cancer; 2017 Feb; 140(4):914-921. PubMed ID: 27813063
[TBL] [Abstract][Full Text] [Related]
24. Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
Di Narzo AF; Tejpar S; Rossi S; Yan P; Popovici V; Wirapati P; Budinska E; Xie T; Estrella H; Pavlicek A; Mao M; Martin E; Scott W; Bosman FT; Roth A; Delorenzi M
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25246611
[TBL] [Abstract][Full Text] [Related]
25. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
[TBL] [Abstract][Full Text] [Related]
26. Complete blood count-based inflammatory score (CBCS) is a novel prognostic marker for gastric cancer patients after curative resection.
Lin JX; Lin JP; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu R; Zheng CH; Huang CM; Li P
BMC Cancer; 2020 Jan; 20(1):11. PubMed ID: 31906893
[TBL] [Abstract][Full Text] [Related]
27. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
[TBL] [Abstract][Full Text] [Related]
28. The prognostic role of the preoperative absolute lymphocyte count and absolute monocyte count in patients with resected advanced melanoma.
Rochet NM; Kottschade LA; Grotz TE; Porrata LF; Markovic SN
Am J Clin Oncol; 2015 Jun; 38(3):252-8. PubMed ID: 23774073
[TBL] [Abstract][Full Text] [Related]
29. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
30. A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients.
Mao M; Wang X; Sheng H; Liu Y; Zhang L; Dai S; Chi PD
BMC Cancer; 2018 Nov; 18(1):1178. PubMed ID: 30486825
[TBL] [Abstract][Full Text] [Related]
31. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
Laino AS; Woods D; Vassallo M; Qian X; Tang H; Wind-Rotolo M; Weber J
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581042
[TBL] [Abstract][Full Text] [Related]
32. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma.
Tas F; Duranyildiz D; Oguz H; Disci R; Kurul S; Yasasever V; Topuz E
Med Oncol; 2005; 22(1):39-44. PubMed ID: 15750195
[TBL] [Abstract][Full Text] [Related]
33. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
Tian M; Yang J; Han J; He J; Liao W
Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
[TBL] [Abstract][Full Text] [Related]
34. A Retrospective Propensity Score Matched Study of the Preoperative C-Reactive Protein to Albumin Ratio and Prognosis in Patients with Resectable Non-Metastatic Breast Cancer.
Zhou L; Ma S; Balde AI; Han S; Cai Z; Li Z
Med Sci Monit; 2019 Jun; 25():4342-4352. PubMed ID: 31182704
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients.
Saiag P; Aegerter P; Vitoux D; Lebbé C; Wolkenstein P; Dupin N; Descamps V; Aractingi S; Funck-Brentano E; Autier P; Dragomir M; Boniol M
J Natl Cancer Inst; 2015 Dec; 107(12):djv264. PubMed ID: 26376687
[TBL] [Abstract][Full Text] [Related]
36. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
[TBL] [Abstract][Full Text] [Related]
37. Preoperative level of serum amyloid A is superior to C-reactive protein in the prognosis of esophageal squamous cell carcinoma.
Meng YQ; Cao X; Wen ZS; Liu QW; Tan ZH; Duan H; Ma GW; Lin P
Dis Esophagus; 2014; 27(7):670-7. PubMed ID: 24033446
[TBL] [Abstract][Full Text] [Related]
38. Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma.
Hügel R; Muendlein A; Volbeding L; Drexel H; Richtig E; Wehkamp U; Painsi C; Lange-Asschenfeldt B; Hauschild A; Egberts F
Melanoma Res; 2016 Aug; 26(4):354-60. PubMed ID: 27206057
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer.
Kwon KA; Kim SH; Oh SY; Lee S; Han JY; Kim KH; Goh RY; Choi HJ; Park KJ; Roh MS; Kim HJ; Kwon HC; Lee JH
BMC Cancer; 2010 May; 10():203. PubMed ID: 20465852
[TBL] [Abstract][Full Text] [Related]
40. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
Kirkwood JM; Ibrahim JG; Sondak VK; Richards J; Flaherty LE; Ernstoff MS; Smith TJ; Rao U; Steele M; Blum RH
J Clin Oncol; 2000 Jun; 18(12):2444-58. PubMed ID: 10856105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
